The score was predictive of sensitivity to MEK and BRAF inhibitors across many cancer cell lines, and was significantly associated with progression-free survival (PFS) in retrospective analyses of patients treated with vemurafenib, a selective inhibitor of the mutated BRAF(V600E) kinase. This evidence concerns the gene BRAF and cancer.